Insilico Medicine has entered a multi-year collaboration with Servier, valued at up to US$888 million, to accelerate the discovery and development of novel oncology therapies. The partnership combines Insilico’s AI-driven drug discovery platform, Pharma.AI, with Servier’s global expertise in clinical development and commercialization of cancer treatments.
Under the agreement, Insilico will receive up to US$32 million in upfront and near-term R&D payments to identify potential drug candidates using its AI technology. Servier will share research and development costs and take the lead on clinical validation, regulatory approvals, and worldwide commercialization of successful candidates. The collaboration targets challenging cancer indications, leveraging Insilico’s expertise in both novel and established therapeutic mechanisms.
Insilico has already built a robust oncology pipeline, including programs such as the pan-TEAD inhibitor ISM6331 and the MAT2A inhibitor ISM3412, both undergoing global Phase I clinical trials. Four additional oncology programs have been fully or partially out-licensed, with early-stage clinical trials actively in progress.
The company has demonstrated accelerated preclinical development timelines, nominating 20 preclinical candidates from 2021 to 2024 with an average development period of 12–18 months per program, significantly shorter than the industry average of 4–5 years.
The collaboration highlights the growing role of AI and automation in pharmaceutical R&D, aiming to streamline early-stage discovery, improve candidate selection, and expedite the translation of innovative therapies into clinical use.
